Market Overview:
The global pancreatic and bile duct cancer drug market is expected to grow at a CAGR of 10.8% from 2018 to 2030. The market growth is attributed to the increasing incidence of pancreatic and bile duct cancer, rising demand for novel therapies, and growing awareness about these cancers. Based on type, the global pancreatic and bile duct cancer drug market is segmented into vascular endothelial growth factor receptors (VEGFRs), programmed cell death protein 1 (PD-1), signal transducer activator of transcription 3 (STAT3), and others. The VEGFRs segment is expected to account for the largest share of the global pancreatic and bile duct cancer drug market in 2018. This segment is projected to grow at a CAGR of 11% from 2018 to 2030 due to the high prevalence of VEGFR-positive tumors across different regions. Based on application, the global pancreatic and bile duct cancer drug market is divided into Pancreatic Cancer, Cholangiocarcinoma (CCA), Others). The Pancreatic Cancer segment accounted for the largest share of this market in 2017 owingto its high incidence rate worldwide.
Product Definition:
Pancreatic and Bile Duct Cancer Drug is a drug used to treat pancreatic and bile duct cancer. The importance of this drug is that it can help to improve the survival rates for people with these cancers.
Vascular Endothelial Growth Factor Receptors:
Vascular endothelial growth factor receptor (VEGFR) is a protein that acts as a cell surface receptor for vascular endothelial growth factor. It is also known as Flk-1 or platelet-derived growth factor receptor. The presence of the ligand vascular endothelial growth factor on the cell surface, stimulates the tyrosine kinase activity of these receptors and thereby regulates cellular proliferation, differentiation and apoptosis.
Programmed Cell Death Protein 1:
PD-1 is a member of the PD family of nuclear proteins. It was initially identified as a tumor suppressor in non-small cell lung cancer (NSCLC) and later found to be involved in the regulation of adaptive immune response by binding to PD-L1 on T cells.
Application Insights:
Pancreatic cancer accounted for the largest share in 2015 owing to its high prevalence rate. It is estimated that around 5-10% of all pancreatic cancers are hereditary and occur due to a mutation in the TP53 gene. This gene encodes a tumor suppressor protein which regulates cell growth, apoptosis, and differentiation processes. The increasing consumption of alcohol and exposure to carcinogenic elements such as tobacco smoke are factors responsible for the increased incidence rate of pancreatic cancer over the world.
The bile duct cancer segment is expected to witness lucrative growth during forecast years due to rising incidences of cholangiocarcinoma across the globe.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of key players, increased research activities, and high healthcare expenditure in this region. Moreover, a higher prevalence of chronic pancreatitis is also contributing toward regional growth. According to an article published by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Pancreatic Cancer Awareness Month (PCAM) is observed during the month of March every year in North America with a purpose to increase awareness about pancreatic cancer among people living throughout this region as well as worldwide.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to increasing disposable income levels coupled with rising consumer awareness regarding early diagnosis & treatment options for various cancers including biliary tract cancer.
Growth Factors:
- Increasing incidence of pancreatic and bile duct cancer
- Growing demand for better treatment options for pancreatic and bile duct cancer
- Rising awareness about pancreatic and bile duct cancer among people
- Technological advancements in the diagnosis and treatment of pancreatic and bile duct cancer
- Availability of government funding for research on pancreatic and bile duct cancer
Scope Of The Report
Report Attributes
Report Details
Report Title
Pancreatic and Bile Duct Cancer Drug Market Research Report
By Type
Vascular Endothelial Growth Factor Receptors, Programmed Cell Death Protein 1, Signal Transducer Activator of Transcription 3, Others
By Application
Pancreatic Cancer, Cholangiocarcinoma
By Companies
3-V Biosciences Inc, 4P-Pharma SAS, 4SC AG, AB Science SA, AbbVie Inc, AbGenomics International Inc, Ability Pharmaceuticals SL, Aclaris Therapeutics Inc, Actuate Therapeutics Inc, Aduro BioTech Inc, Advantagene Inc, AGV Discovery SAS, AIMM Therapeutics BV, Alissa Pharma, Alligator Bioscience AB, Allinky Biopharma, Altor BioScience Corp, amcure GmbH, Amgen Inc, Amplia Therapeutics Pty Ltd, Anavex Life Sciences Corp, Andarix Pharmaceuticals Inc, ANP Technologies Inc, AntiCancer Inc, APEIRON Biologics AG, Apexigen Inc, Aphios Corp, Aposense Ltd, ARMO Biosciences Inc, ArQule Inc
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
214
Number of Tables & Figures
150
Customization Available
Yes, the report can be customized as per your need.
Global Pancreatic and Bile Duct Cancer Drug Market Report Segments:
The global Pancreatic and Bile Duct Cancer Drug market is segmented on the basis of:
Types
Vascular Endothelial Growth Factor Receptors, Programmed Cell Death Protein 1, Signal Transducer Activator of Transcription 3, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Pancreatic Cancer, Cholangiocarcinoma
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- 3-V Biosciences Inc
- 4P-Pharma SAS
- 4SC AG
- AB Science SA
- AbbVie Inc
- AbGenomics International Inc
- Ability Pharmaceuticals SL
- Aclaris Therapeutics Inc
- Actuate Therapeutics Inc
- Aduro BioTech Inc
- Advantagene Inc
- AGV Discovery SAS
- AIMM Therapeutics BV
- Alissa Pharma
- Alligator Bioscience AB
- Allinky Biopharma
- Altor BioScience Corp
- amcure GmbH
- Amgen Inc
- Amplia Therapeutics Pty Ltd
- Anavex Life Sciences Corp
- Andarix Pharmaceuticals Inc
- ANP Technologies Inc
- AntiCancer Inc
- APEIRON Biologics AG
- Apexigen Inc
- Aphios Corp
- Aposense Ltd
- ARMO Biosciences Inc
- ArQule Inc
Highlights of The Pancreatic and Bile Duct Cancer Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Vascular Endothelial Growth Factor Receptors
- Programmed Cell Death Protein 1
- Signal Transducer Activator of Transcription 3
- Others
- By Application:
- Pancreatic Cancer
- Cholangiocarcinoma
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Pancreatic and Bile Duct Cancer Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Pancreatic cancer drug is a medication that is used to treat pancreatic cancer. Pancreatic cancer is a type of cancer that grows in the pancreas, an organ near the stomach. The pancreas helps make digestive juices and hormones.
Some of the major players in the pancreatic and bile duct cancer drug market are 3-V Biosciences Inc, 4P-Pharma SAS, 4SC AG, AB Science SA, AbbVie Inc, AbGenomics International Inc, Ability Pharmaceuticals SL, Aclaris Therapeutics Inc, Actuate Therapeutics Inc, Aduro BioTech Inc, Advantagene Inc, AGV Discovery SAS, AIMM Therapeutics BV, Alissa Pharma, Alligator Bioscience AB, Allinky Biopharma, Altor BioScience Corp, amcure GmbH, Amgen Inc, Amplia Therapeutics Pty Ltd, Anavex Life Sciences Corp, Andarix Pharmaceuticals Inc, ANP Technologies Inc, AntiCancer Inc, APEIRON Biologics AG, Apexigen Inc, Aphios Corp, Aposense Ltd, ARMO Biosciences Inc, ArQule Inc.
The pancreatic and bile duct cancer drug market is expected to register a CAGR of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Pancreatic and Bile Duct Cancer Drug Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Pancreatic and Bile Duct Cancer Drug Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Pancreatic and Bile Duct Cancer Drug Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Pancreatic and Bile Duct Cancer Drug Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Pancreatic and Bile Duct Cancer Drug Market Size & Forecast, 2018-2028
4.5.1 Pancreatic and Bile Duct Cancer Drug Market Size and Y-o-Y Growth
4.5.2 Pancreatic and Bile Duct Cancer Drug Market Absolute $ Opportunity
Chapter 5 Global Pancreatic and Bile Duct Cancer Drug Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Pancreatic and Bile Duct Cancer Drug Market Size Forecast by Type
5.2.1 Vascular Endothelial Growth Factor Receptors
5.2.2 Programmed Cell Death Protein 1
5.2.3 Signal Transducer Activator of Transcription 3
5.2.4 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Pancreatic and Bile Duct Cancer Drug Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Pancreatic and Bile Duct Cancer Drug Market Size Forecast by Applications
6.2.1 Pancreatic Cancer
6.2.2 Cholangiocarcinoma
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Pancreatic and Bile Duct Cancer Drug Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Pancreatic and Bile Duct Cancer Drug Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Pancreatic and Bile Duct Cancer Drug Analysis and Forecast
9.1 Introduction
9.2 North America Pancreatic and Bile Duct Cancer Drug Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Pancreatic and Bile Duct Cancer Drug Market Size Forecast by Type
9.6.1 Vascular Endothelial Growth Factor Receptors
9.6.2 Programmed Cell Death Protein 1
9.6.3 Signal Transducer Activator of Transcription 3
9.6.4 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Pancreatic and Bile Duct Cancer Drug Market Size Forecast by Applications
9.10.1 Pancreatic Cancer
9.10.2 Cholangiocarcinoma
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Pancreatic and Bile Duct Cancer Drug Analysis and Forecast
10.1 Introduction
10.2 Europe Pancreatic and Bile Duct Cancer Drug Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Pancreatic and Bile Duct Cancer Drug Market Size Forecast by Type
10.6.1 Vascular Endothelial Growth Factor Receptors
10.6.2 Programmed Cell Death Protein 1
10.6.3 Signal Transducer Activator of Transcription 3
10.6.4 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Pancreatic and Bile Duct Cancer Drug Market Size Forecast by Applications
10.10.1 Pancreatic Cancer
10.10.2 Cholangiocarcinoma
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Pancreatic and Bile Duct Cancer Drug Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Pancreatic and Bile Duct Cancer Drug Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Pancreatic and Bile Duct Cancer Drug Market Size Forecast by Type
11.6.1 Vascular Endothelial Growth Factor Receptors
11.6.2 Programmed Cell Death Protein 1
11.6.3 Signal Transducer Activator of Transcription 3
11.6.4 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Pancreatic and Bile Duct Cancer Drug Market Size Forecast by Applications
11.10.1 Pancreatic Cancer
11.10.2 Cholangiocarcinoma
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Pancreatic and Bile Duct Cancer Drug Analysis and Forecast
12.1 Introduction
12.2 Latin America Pancreatic and Bile Duct Cancer Drug Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Pancreatic and Bile Duct Cancer Drug Market Size Forecast by Type
12.6.1 Vascular Endothelial Growth Factor Receptors
12.6.2 Programmed Cell Death Protein 1
12.6.3 Signal Transducer Activator of Transcription 3
12.6.4 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Pancreatic and Bile Duct Cancer Drug Market Size Forecast by Applications
12.10.1 Pancreatic Cancer
12.10.2 Cholangiocarcinoma
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Pancreatic and Bile Duct Cancer Drug Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Pancreatic and Bile Duct Cancer Drug Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Pancreatic and Bile Duct Cancer Drug Market Size Forecast by Type
13.6.1 Vascular Endothelial Growth Factor Receptors
13.6.2 Programmed Cell Death Protein 1
13.6.3 Signal Transducer Activator of Transcription 3
13.6.4 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Pancreatic and Bile Duct Cancer Drug Market Size Forecast by Applications
13.10.1 Pancreatic Cancer
13.10.2 Cholangiocarcinoma
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Pancreatic and Bile Duct Cancer Drug Market: Competitive Dashboard
14.2 Global Pancreatic and Bile Duct Cancer Drug Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 3-V Biosciences Inc
14.3.2 4P-Pharma SAS
14.3.3 4SC AG
14.3.4 AB Science SA
14.3.5 AbbVie Inc
14.3.6 AbGenomics International Inc
14.3.7 Ability Pharmaceuticals SL
14.3.8 Aclaris Therapeutics Inc
14.3.9 Actuate Therapeutics Inc
14.3.10 Aduro BioTech Inc
14.3.11 Advantagene Inc
14.3.12 AGV Discovery SAS
14.3.13 AIMM Therapeutics BV
14.3.14 Alissa Pharma
14.3.15 Alligator Bioscience AB
14.3.16 Allinky Biopharma
14.3.17 Altor BioScience Corp
14.3.18 amcure GmbH
14.3.19 Amgen Inc
14.3.20 Amplia Therapeutics Pty Ltd
14.3.21 Anavex Life Sciences Corp
14.3.22 Andarix Pharmaceuticals Inc
14.3.23 ANP Technologies Inc
14.3.24 AntiCancer Inc
14.3.25 APEIRON Biologics AG
14.3.26 Apexigen Inc
14.3.27 Aphios Corp
14.3.28 Aposense Ltd
14.3.29 ARMO Biosciences Inc
14.3.30 ArQule Inc
